{"id":627760,"date":"2022-11-29T16:28:02","date_gmt":"2022-11-29T16:28:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=627760"},"modified":"2022-11-29T16:28:02","modified_gmt":"2022-11-29T16:28:02","slug":"cervical-cancer-pipeline-analysis-2022-insights-into-the-latest-fda-ema-and-pmda-approvals-clinical-and-nonclinical-trials-emerging-therapies-treatment-algorithm-and-key-players","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cervical-cancer-pipeline-analysis-2022-insights-into-the-latest-fda-ema-and-pmda-approvals-clinical-and-nonclinical-trials-emerging-therapies-treatment-algorithm-and-key-players_627760.html","title":{"rendered":"Cervical Cancer Pipeline Analysis, 2022 | Insights into the Latest FDA, EMA, and PMDA Approvals, Clinical and Non-Clinical Trials, Emerging Therapies, Treatment Algorithm, and Key Players"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585713455.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cervical Cancer Pipeline Analysis, 2022 | Insights into the Latest FDA, EMA, and PMDA Approvals, Clinical and Non-Clinical Trials, Emerging Therapies, Treatment Algorithm, and Key Players\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585713455.jpeg\" alt=\"Cervical Cancer Pipeline Analysis, 2022 | Insights into the Latest FDA, EMA, and PMDA Approvals, Clinical and Non-Clinical Trials, Emerging Therapies, Treatment Algorithm, and Key Players\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">As per DelveInsight\u2019s assessment, globally, about 70+ key pharma and biotech companies are working on 70+ pipeline drugs in the Cervical Cancer therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n<p style=\"text-align: justify;\"><em>The <strong>Cervical Cancer Therapeutics Market<\/strong> dynamics are set to change in the coming years owing to the positive outcomes of the drug candidates during the developmental stage by key players. The launch of the upcoming therapies has the potential to create a significant positive shift in the cervical cancer therapeutics market size in the coming years.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&ldquo;<strong>Cervical Cancer Pipeline Insight, 2022<\/strong>&#8221; report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the&nbsp; Cervical Cancer Market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Cervical Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" title=\"Cervical Cancer Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/acea59c937b3ae54088da9bf71bed120.jpg\" alt=\"Cervical Cancer Pipeline Analysis\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cervical-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Cervical Cancer Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about emerging therapies for the&nbsp;<strong>treatment&nbsp;of Cervical Cancer<\/strong>&nbsp;and the aggregate therapies developed by major pharma companies.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for&nbsp;<strong>Cervical Cancer Treatment.<\/strong><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the&nbsp;<strong>Cervical Cancer market.<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn How the Ongoing Clinical &amp; Commercial Activities will Affect the Cervical Cancer Therapeutic Segment @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cervical-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>&nbsp;https:\/\/www.delveinsight.com\/sample-request\/cervical-cancer-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cervical Cancer Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Globally, there are approx. <strong>70+ key companies<\/strong> which are developing therapies for Cervical Cancer. Currently, <strong>Advaxis<\/strong> has its Cervical Cancer drug candidates in the most advanced stage of clinical development.&nbsp;<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Leading Companies in the Cervical Cancer Therapeutics Market Include:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Regeneron Pharmaceuticals, Jiangsu Hengrui Medicine, Akeso Biopharma, Celgene\/MedImmune, Henlix Biotech, Zeria, Advaxis, Akeso Biopharma, AnGes, Advenchen Laboratories\/Jiangsu Chia Tai Tianqing Pharmaceutical, Valent recombinant vaccine &#8211; National Vaccine and Serum Institute, Xiamen Innovax Biotech, Genentech, Celgene\/MedImmune, Bristol-Myers Squibb, Ono Pharmaceuticals, InnoMab, BeiGene, Agenus\/Ludwig Institute for Cancer Research, EMD Serono, Merck, Apollomics, Immunitor, Genentech, Arcus Biosciences, Guangzhou Gloria Biosciences, Taiho Pharmaceutical, Innovent Biologics, Clovis Oncology, Janssen, GlaxoSmithKline, Iovance Biotherapeutics, and others.&nbsp;<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cervical Cancer Therapies Covered in the Report Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Axalimogene filolisbac:<\/strong> Advaxis<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Camrelizumab:<\/strong> Jiangsu HengRui Medicine Co., Ltd.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>AK104:<\/strong> Akeso<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Durvalumab:&nbsp;<\/strong>AstraZeneca&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>HLX10:&nbsp;<\/strong>Shanghai Henlius Biotech&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cervical-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/cervical-cancer-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Cervical Cancer Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Cervical Cancer &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Cervical Cancer Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Cervical Cancer Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Cervical Cancer Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Cervical Cancer Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Cervical Cancer Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Key Companies in the Cervical Cancer Market<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Key Products in the Cervical Cancer Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Cervical Cancer Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Cervical Cancer Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Cervical Cancer Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em><strong>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF to Explore the Key Offerings of the Report @&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cervical-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/cervical-cancer-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Trending Healthcare Reports By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cervical-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Cervical Cancer Market Outlook 2032<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s &#8220;Cervical Cancer Market Insights, Epidemiology, and Market Forecast 2032&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Cervical Cancer market size, share, and trend analysis for the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan).<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cervical-cancer-pipeline-analysis-2022-insights-into-the-latest-fda-ema-and-pmda-approvals-clinical-and-nonclinical-trials-emerging-therapies-treatment-algorithm-and-key-players\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cervical-cancer-pipeline-analysis-2022-insights-into-the-latest-fda-ema-and-pmda-approvals-clinical-and-nonclinical-trials-emerging-therapies-treatment-algorithm-and-key-players\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP As per DelveInsight\u2019s assessment, globally, about 70+ key pharma and biotech companies are working on 70+ pipeline drugs in the Cervical Cancer therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cervical-cancer-pipeline-analysis-2022-insights-into-the-latest-fda-ema-and-pmda-approvals-clinical-and-nonclinical-trials-emerging-therapies-treatment-algorithm-and-key-players_627760.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,425,426,417,404],"tags":[],"class_list":["post-627760","post","type-post","status-publish","format-standard","hentry","category-Business","category-Finance","category-Financial-Market","category-Marketing-Sales","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/627760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=627760"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/627760\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=627760"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=627760"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=627760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}